Related references
Note: Only part of the references are listed.Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia
Faiqa Farrukh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Specialized regulatory T cells control venous blood clot resolution through SPARC
Fatemeh Shahneh et al.
BLOOD (2021)
No Impact of the Increased Number of Cardiovascular Risk Factors on Thrombosis and Survival in Polycythemia Vera
Ivan Krecak et al.
ONCOLOGY RESEARCH AND TREATMENT (2021)
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2021)
SPARCing the clot
Bram van Os et al.
BLOOD (2021)
Inflammation, Infection and Venous Thromboembolism
Meaghan E. Colling et al.
CIRCULATION RESEARCH (2021)
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Ayalew Tefferi et al.
LEUKEMIA (2021)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Salvatrice Mancuso et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner et al.
CELLS (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia
Dian Zhou et al.
LEUKEMIA RESEARCH (2018)
Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update
Maxwell E. Afari et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2016)
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
Lamia Lamrani et al.
BLOOD (2014)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging
T. P. Santisakultarm et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis
Tiziano Barbui et al.
BLOOD (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Thrombosis as an intravascular effector of innate immunity
Bernd Engelmann et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease
Angela Papa et al.
CLINICA CHIMICA ACTA (2008)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Which white blood cell subtypes predict increased cardiovascular risk?
BD Horne et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
